WHO naming stem · infix · 44 listed names
-ki(n)-
This page was written with AI.
target: interleukin
Where it sits in a name
WHO writes the stem as -ki(n)-. It has 2 spellings or places: kin inside the name, with letters before and after it (…kin…); ki inside the name, with letters before and after it (…ki…).
Of the 44 names WHO lists under it, 6 carry kin inside the name, with letters before and after it, 38 carry ki inside the name, with letters before and after it.
All 44 names WHO lists under -ki(n)-
These are the INN in group (a) of Part IV of the stem book: names in which WHO says the stem is used as defined. The stem is marked where WHO places it. A-Z as WHO lists them.
Beside each name: the brand names it appears under in the US list (FDA Drugs@FDA) and the EU central list (EMA), or that neither list carries it. 12 of 44 names appear in these lists: 12 in the US list (FDA Drugs@FDA) and 11 in the EU central list (EMA); 11 have national brands in at least one EU/EEA country. Each brand opens in this site's brand lookup. A name is found when the agency's ingredient name is the same name once salt words such as hydrochloride or sodium are set aside (the list of those words); where WHO's own name carries such a word (estradiol valerate), the agency must write the same words. A spelling that differs only by the INN letter rules (ph for f, y for i) is found too and shown. Under each name that one or more EU/EEA countries authorise under a national brand of their own (through that country's agency, so not in the EU central list), a line now gives the number of those countries and their codes, from EMA's Article 57 data, and opens the country lookup at that name. A name with none of these lines may still be sold elsewhere, or in Europe only under its own generic name.
- abrezekimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- avizakimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- bermekimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- bimekizumabUS brands: BIMZELXEU (central) brands: Bimzelx
- briakinumabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- camoteskimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- canakinumabUS brands: ILARISEU (central) brands: Ilaris
- cendakimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- cergutuzumab amunaleukinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- clazakizumabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- depemokimabUS brands: EXDENSUREU (central) brands: Exdensur
- ebdarokimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- eblasakimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- enokizumabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- etokimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- fezakinumabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- gevokizumabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- gumokimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- itepekimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- ixekizumabUS brands: TALTZEU (central) brands: Taltz
- lebrikizumabUS brands: EBGLYSSEU (central) brands: Ebglyss
- lusvertikimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- lutikizumabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- manfidokimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- mirikizumabUS brands: OMVOHEU (central) brands: Omvoh
- netakimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- olokizumabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- ordesekimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- perakizumabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- pivekimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- pivekimab sunirineUS brands: DECNUPAZEU (central) brands: none found
- risankizumabUS brands: SKYRIZIEU (central) brands: Skyrizi
- romilkimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- secukinumabUS brands: COSENTYXEU (central) brands: Cosentyx
- sonelokimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- tildrakizumabUS brands: ILUMYAEU (central) brands: Ilumetri
- torudokimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- tozorakimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- tralokinumabUS brands: ADBRYEU (central) brands: Adtralza
- tucotuzumab celmoleukinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- ustekinumab
- vunakizumabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- xeligekimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- ziltivekimabNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
US list: Drugs@FDA, from the FDA Drugs@FDA data (openFDA bulk file), checked . It keeps discontinued brands, marked here as FDA marks them.
EU (central) list: EMA medicines list, European Medicines Agency (EMA), checked . Medicines authorised for the whole EU through EMA only: a brand authorised by one country's own agency is not in it. Source: European Medicines Agency (EMA), medicines list, checked 2026-09-24.
EU/EEA national lists: European Medicines Agency (EMA), Article 57 product data, downloaded (EMA's Article 57 page). Brand names authorised by each country's own agency, as the country lookup reads them; a product named after its substance and maker ("Paracetamol Teva") is not counted as a brand, and EU central authorisations are not counted as a country. GB in a list is Northern Ireland, which EMA's data carries alongside the EU/EEA countries.
Decode another name
Decoded
briakinumab
Listed INNCarries 2 WHO stems, most specific first: -ki(n)- …
- -ki(n)-inside the nameWHO lists it hereWHO definition: target: interleukin
- -mabend of the nameWHO lists it hereWHO definition: monoclonal antibodies (previous naming scheme)
“briakinumab” is an INN that WHO lists under -ki(n)-, -mab in the 2024 stem book.
The same decoder as the front page: it reads the letters of a name against all 482 WHO stems, in your browser.
Source and licence
The definition of -ki(n)- (Part II B) and the 44 names (Part IV, group (a)) are from Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024 (World Health Organization, Stem book 2024 (ISBN 978-92-4-009938-8); covers proposed INN Lists 1-129). Checked .
Adapted from: Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. This adaptation was not created by WHO; WHO is not responsible for its content or accuracy and does not endorse this site. The data file stems.json is shared under the same licence.